Bayer’s factor XIa inhibitor slashed the risk of recurrent stroke in a late-stage trial in certain patients, breathing new life into a class of drugs that has suffered a string of high-profile failures.
The unexpected …
A record-setting $3.2 billion in biotech follow-on stock offerings were sold over the last 24 hours, another indication of public investors’ appetite for the sector.
VC firm Apple Tree Partners filed for voluntary Chapter 11 relief in US bankruptcy court on Wednesday, seeking to restructure and keep its portfolio afloat
USAntibiotics on Tuesday won approval for its American-made version of extended-release amoxicillin, about two months faster than normal. It is the first product to win
CDMO Adare Pharma Solutions is closing a facility in Philadelphia and letting go of 137 workers, a little over a year after relocating its headquarters
The FDA on Tuesday approved a gene therapy for a rare immune disease called Wiskott-Aldrich syndrome, for which patients have little options besides a bone
Bayer’s factor XIa inhibitor slashed the risk of recurrent stroke in a late-stage trial in certain patients, breathing new life into a class of drugs that has suffered a string of high-profile failures.
The unexpected …